InfuSystem Q1 EPS Beats at $0.05 While Revenue Drops 3% to $33.7M
InfuSystem Holdings reported Q1 2026 EPS of $0.05, surpassing estimates by one cent and swinging from a $0.01 loss a year earlier. Revenue fell 3% year-over-year to $33.68 million, with Device Solutions revenue down 17% offset partially by a 6% gain in Patient Services to $22.10 million.
1. Q1 Financial Results
InfuSystem Holdings delivered Q1 2026 EPS of $0.05, topping estimates by $0.01 and reversing last year’s $0.01 loss. Total revenue was $33.68 million, down 3% year-over-year, for net income of $1.00 million.
2. Segment Performance
Patient Services revenue rose 6% to $22.10 million, driven by increased demand for infusion therapy support. Device Solutions revenue fell 17% due to lower equipment sales and rentals.
3. Profitability and Balance Sheet
Gross profit increased 3% to $19.70 million, reflecting improved margins in Patient Services. The company maintained a 2.14 current ratio and a 0.39 debt-to-equity ratio, indicating strong liquidity and conservative leverage.